Mihaela Minea | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

Best Researcher Award

Mihaela Minea — Ovidius University of Constanța
Mihaela Minea
Affiliation Ovidius University of Constanța
Country Romania
Scopus ID 58509570100
Documents 65
Citations 67
h-index 4
Subject Area Personalized Medicine
Event International Top Pharmaceutical Awards

Mihaela Minea is associated with Ovidius University of Constanța, Romania, and has contributed to the interdisciplinary field of personalized medicine, rehabilitation sciences, and clinical evaluation methodologies. Her academic profile reflects scholarly engagement in rehabilitation assessment, gait analysis, and evidence-based healthcare approaches relevant to modern pharmaceutical and therapeutic research practices.[1] Her publication activity and citation profile demonstrate continuing participation in applied medical research with emphasis on patient-centered clinical outcomes and rehabilitation innovation.[2]

Abstract

This academic recognition article presents an overview of the scholarly profile and research contributions of Mihaela Minea in the domain of personalized medicine and rehabilitation sciences. Her work includes research on computerized gait analysis, rehabilitation outcomes, and clinical assessment methodologies. The research profile demonstrates involvement in interdisciplinary healthcare research integrating rehabilitation sciences with evidence-based medical evaluation frameworks. The publication record and citation activity indicate continuing academic participation in applied medical and pharmaceutical research relevant to patient-centered healthcare advancement.[1][3]

Keywords

Personalized Medicine, Rehabilitation Sciences, Clinical Research, Gait Analysis, Evidence-Based Medicine, Pharmaceutical Research, Osteoarthritis Rehabilitation, Healthcare Innovation, Medical Assessment, Research Evaluation

Introduction

Personalized medicine has become an important area within modern healthcare systems due to its focus on individualized therapeutic strategies, rehabilitation optimization, and patient-centered clinical interventions. Researchers working in this field contribute to the development of assessment methodologies that improve rehabilitation outcomes and evidence-based healthcare decision-making. Mihaela Minea has participated in research activities related to rehabilitation analysis and clinical outcome assessment, particularly within gait evaluation and osteoarthritis rehabilitation studies.[2] Such investigations support broader advancements in clinical rehabilitation sciences and therapeutic monitoring systems relevant to pharmaceutical and healthcare applications.[4]

Research Profile

The research profile of Mihaela Minea includes scholarly contributions indexed within Scopus author databases and related scientific platforms. Her documented academic activities involve publications associated with rehabilitation medicine, gait analysis technologies, and clinical healthcare evaluation systems.[1] The available citation metrics indicate an active contribution to interdisciplinary medical research with recognized engagement in healthcare-oriented investigations. The combination of publication records, citation activity, and subject specialization demonstrates sustained involvement in patient-focused rehabilitation studies and evidence-driven clinical methodologies.[5]

Research Contributions

The documented research contributions of Mihaela Minea include involvement in studies examining rehabilitation outcomes and computerized gait analysis systems for patients affected by knee osteoarthritis. These studies contribute to the understanding of rehabilitation effectiveness and objective clinical evaluation approaches in musculoskeletal healthcare management.[2] Research activities in rehabilitation sciences are increasingly relevant for modern healthcare systems because they support therapeutic optimization, monitoring strategies, and individualized rehabilitation planning. The integration of digital analysis tools into rehabilitation research also reflects broader trends in precision medicine and data-informed healthcare delivery.[6]

Publications

Selected scientific publications associated with Mihaela Minea demonstrate research interest in rehabilitation science, clinical assessment methodologies, and gait analysis applications in osteoarthritis rehabilitation.[2] These publications contribute to the broader scientific understanding of rehabilitation monitoring and healthcare evaluation systems relevant to personalized therapeutic approaches.[3]

Research Impact

Research impact within rehabilitation sciences is often evaluated through publication indexing, citation activity, and interdisciplinary relevance. The available citation record associated with Mihaela Minea indicates academic recognition within clinical and rehabilitation research communities.[1] Her scholarly work contributes to evidence-based rehabilitation practices and supports continuing discussions regarding digital clinical assessment technologies and patient-centered rehabilitation models. Such contributions are relevant to healthcare professionals, rehabilitation specialists, and medical researchers interested in outcome-oriented therapeutic evaluation systems.[4]

Award Suitability

Mihaela Minea demonstrates suitability for recognition through the Best Researcher Award based on her documented academic contributions, indexed research profile, and participation in rehabilitation and personalized medicine studies. Her scholarly activities align with the objectives of the International Top Pharmaceutical Awards, which recognize meaningful scientific engagement and interdisciplinary healthcare research contributions.[5] The combination of research activity, publication records, and citation visibility supports recognition within professional academic and clinical research environments. Her contributions further reflect continuing efforts toward evidence-based rehabilitation assessment and healthcare innovation.[6]

Conclusion

Mihaela Minea has contributed to the advancement of rehabilitation sciences and personalized medicine through scholarly participation in gait analysis and clinical rehabilitation research. Her academic profile reflects interdisciplinary engagement in evidence-based healthcare methodologies and rehabilitation assessment systems. The indexed research record, citation activity, and continuing relevance of her scientific work support recognition within professional medical and pharmaceutical research communities. These contributions remain relevant to contemporary discussions surrounding patient-centered healthcare, rehabilitation optimization, and digital clinical evaluation technologies.[1][3]

References

  1. Elsevier. (n.d.). Scopus author details: Mihaela Minea, Author ID 58509570100. Scopus.https://www.scopus.com/authid/detail.uri?authorId=58509570100
  2. Minea, M., et al. (2023). Using Computerised Gait Analysis to Assess Changes After Rehabilitation in Knee Osteoarthritis: A Systematic Review and Meta-Analysis of Gait Speed Improvement. Healthcare.DOI: https://doi.org/10.3390/healthcare11050639

juan iovanna | Personalized Medicine | Best Researcher Award

Published on by Top Pharmaceutical

juan iovanna | Personalized Medicine | Best Researcher Award

Prof. Dr. juan iovanna, INSERM, France

Prof. Dr. Juan Iovanna è un medico e ricercatore internazionale esperto in oncologia, specializzato nello studio del carcinoma pancreatico. Laureato e dottorato all’Università di Buenos Aires, lavora in Francia dal 1991 presso l’INSERM, dove ha raggiunto il grado di Direttore di Ricerca di Classe Eccezionale. Co-dirige il gruppo “Biologia del cancro pancreatico” al CRCM di Marsiglia e presiede il Programma G7 Cancer. Fondatore di tre start-up biotecnologiche, ha pubblicato 472 articoli con oltre 43.500 citazioni 📚. La sua missione è migliorare la prognosi del tumore pancreatico attraverso ricerca e innovazione terapeutica.

Publication Profile

orcid

Education

Prof. Dr. Juan Iovanna began his academic journey with a degree in Medicine from the University of Buenos Aires, Argentina, in 1982. Driven by a passion for biomedical research, he pursued a Ph.D. in Biomedical Sciences at the same university, which he completed in 1986. 🧬 His doctoral thesis, titled “Meccanismi di regolazione della sintesi proteica in modelli cellulari di stress,” focused on the mechanisms regulating protein synthesis in cellular stress models. 🧪 This foundational work laid the groundwork for his future contributions to medical science and molecular biology.

Experience

🔬 Prof. Dr. Juan Iovanna has built an illustrious career in cancer research. In 1991, he began as a researcher at INSERM in France and was promoted to Research Director in 1993 and again in 1998. 🚀 In 2011, he achieved the prestigious title of Directeur de Recherche de Classe Exceptionnelle (DRCE). From 2011 to 2023, he served as Vice-Director of the Marseille Cancer Research Center (CRCM) and led its Translational Medicine Department. 🧫 He also directed the “Pancreatic Cancer Biology” group from 1999 to 2023. Since 2024, he co-directs this group with Dr. Nelson Dusetti and serves as Emeritus Research Director.

Distinctions and Awards

Prof. Dr. Juan Iovanna has received numerous prestigious awards and honors throughout his career. In 2017, he was awarded the Jean Valade Prize by the Fondation de France for his outstanding contributions to biomedical research. 🌍 In 2018, he received the RAICES Award from Argentina’s Ministry of Science, Technology, and Innovation. 🇫🇷 In 2021, the French Senate honored him with a commemorative medal. In 2023, he was named Honorary Professor at the National University Arturo Jauretche (UNAJ), and in 2024, he was recognized as a Distinguished and Honorary Member of the University of Buenos Aires.

Research Focus

Prof. Dr. Juan Iovanna’s research is centered on precision oncology, with a primary focus on pancreatic ductal adenocarcinoma (PDAC). His work integrates transcriptomics, drug resistance mechanisms, redox metabolism, and multi-omics modeling to uncover novel therapeutic vulnerabilities and biomarkers. He contributes to the development of RNA signatures (like GemPred) to predict chemotherapy response, and investigates KRAS inhibition and therapy-induced senescence as pathways to reverse drug resistance. His translational studies aim to optimize personalized treatment strategies for pancreatic cancer patients, bridging molecular insights with clinical application.

Publication Top Notes

KRAS inhibition reverses chemotherapy resistance promoted by therapy-induced senescence-like in pancreatic ductal adenocarcinoma

The PancreasView gemcitabine transcriptomic signature predicts response to gemcitabine in patients with resected pancreatic ductal adenocarcinoma

Adaptation of redox metabolism in drug-tolerant persister cells is a vulnerability to prevent relapse in pancreatic cancer

Reply to the Letter to the Editor regarding ‘Chi-squared and P-values vs. machine learning feature selection by Y. Takefuji’

Reply to the Letter to the Editor ‘AI-assisted personalized adjuvant chemotherapy in patients with pancreatic ductal adenocarcinoma’ by Y. Shimazu

Prediction of Adjuvant Gemcitabine Sensitivity in Resectable Pancreatic Adenocarcinoma Using the GemPred RNA Signature: An Ancillary Study of the PRODIGE-24/CCTG PA6 Clinical Trial
Inhibition of glucuronidation in pancreatic cancer improves gemcitabine anticancer activity
Limitation and challenges in using pancreatic cancer‐derived organoids as a preclinical tool

Multi-omics data integration and modeling unravels new mechanisms for pancreatic cancer and improves prognostic prediction